Endo’s Lidoderm Marketing Practices Under HHS OIG Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
Subpoena asks for documents relating to off-label promotion of pain patch.
You may also be interested in...
Watson’s Generic Lidoderm Approval Leaves Questions About Exclusivity
FDA will not decide whether the first-filer is entitled to 180 days of marketing protection until another ANDA is ready for full approval. Watson “believes” it holds marketing exclusivity for Endo’s pain patch even though it failed to obtain tentative approval within the statutory 30-month timeframe.
Business News, In Brief
Updates on Sandoz' enoxaparin, J&J's Hep C business, Abbott and Watson.
Endo To Submit Response To FDA On Lidoderm Bioequivalence Recommendation
Endo argues bioequivalence of the lidocaine patch should be demonstrated through clinical efficacy study, not pharmacokinetic data.